REVB vs. EGRX, AIMD, ADXN, OBSV, NLSP, SNGX, ORGS, VRAX, RDHL, and VIRX
Should you be buying Revelation Biosciences stock or one of its competitors? The main competitors of Revelation Biosciences include Eagle Pharmaceuticals (EGRX), Ainos (AIMD), Addex Therapeutics (ADXN), ObsEva (OBSV), NLS Pharmaceutics (NLSP), Soligenix (SNGX), Orgenesis (ORGS), Virax Biolabs Group (VRAX), RedHill Biopharma (RDHL), and Viracta Therapeutics (VIRX). These companies are all part of the "pharmaceutical products" industry.
Revelation Biosciences vs.
Eagle Pharmaceuticals (NASDAQ:EGRX) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and community ranking.
Eagle Pharmaceuticals has higher revenue and earnings than Revelation Biosciences.
In the previous week, Eagle Pharmaceuticals and Eagle Pharmaceuticals both had 1 articles in the media. Revelation Biosciences' average media sentiment score of 0.76 beat Eagle Pharmaceuticals' score of 0.00 indicating that Revelation Biosciences is being referred to more favorably in the news media.
85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Revelation Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Eagle Pharmaceuticals received 382 more outperform votes than Revelation Biosciences when rated by MarketBeat users. Likewise, 67.10% of users gave Eagle Pharmaceuticals an outperform vote while only 63.83% of users gave Revelation Biosciences an outperform vote.
Eagle Pharmaceuticals has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Revelation Biosciences has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500.
Eagle Pharmaceuticals' return on equity of 0.00% beat Revelation Biosciences' return on equity.
Summary
Eagle Pharmaceuticals beats Revelation Biosciences on 9 of the 10 factors compared between the two stocks.
Get Revelation Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revelation Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:REVB) was last updated on 1/22/2025 by MarketBeat.com Staff
